Calcitonin (MIACALCIC - STEOCALCIN): Use Restriction

The European Medicines Agency (EMA) does not recommend long-term use of calcitonin-containing medicines (MIOCALCIC and STEOCALCIN) due to an increased risk of cancer. Moreover, the benefits of these medicines do not outweigh their risks in the treatment of postmenopausal osteoporosis. Only the nasal spray is used for this indication; EMA recommends removing this presentation from the market. The Belgian authorities will take the necessary action when the European Commission has made a decision about it.

See the European press release.

Contact
vig@fagg.be 

Last updated on
05/09/2012